Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $103.44 (market cap $29.10B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is far larger — about 29.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 126 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LQD | MRVI | |
|---|---|---|
Market Cap | $29.10B | $977.37M |
Volume | 33,185,388 | 2,742,564 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $9.00 |
52-Week Low | $101.83 | $2.83 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.55, showing minimal daily movement with a slight decline of -0.03%. The ETF faces bearish technical signals across multiple indicators while maintaining regular dividend distributions. Recent news highlights significant short interest growth of 53.1% in September 2026 and unusual options activity, reflecting heightened market uncertainty amid rising bond yields and geopolitical tensions affecting corporate debt markets.
The investment-grade corporate bond ETF faces headwinds from rising Treasury yields and increased borrowing costs for corporations. While the 4.8% yield provides income appeal, the bearish technical outlook and growing short interest suggest near-term pressure. Key risks include further Fed rate hikes and economic slowdown impacting corporate credit quality.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
